CL2019001617A1 - Preparación líquida parenteral que comprende compuesto de carbamato. - Google Patents
Preparación líquida parenteral que comprende compuesto de carbamato.Info
- Publication number
- CL2019001617A1 CL2019001617A1 CL2019001617A CL2019001617A CL2019001617A1 CL 2019001617 A1 CL2019001617 A1 CL 2019001617A1 CL 2019001617 A CL2019001617 A CL 2019001617A CL 2019001617 A CL2019001617 A CL 2019001617A CL 2019001617 A1 CL2019001617 A1 CL 2019001617A1
- Authority
- CL
- Chile
- Prior art keywords
- liquid preparation
- carbamate compound
- parenteral liquid
- same
- parenteral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170389 | 2016-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001617A1 true CL2019001617A1 (es) | 2019-08-23 |
Family
ID=62559693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001617A CL2019001617A1 (es) | 2016-12-14 | 2019-06-12 | Preparación líquida parenteral que comprende compuesto de carbamato. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12070447B2 (enExample) |
| EP (1) | EP3556349B1 (enExample) |
| JP (1) | JP7110196B2 (enExample) |
| KR (1) | KR102605030B1 (enExample) |
| CN (2) | CN118766839A (enExample) |
| AU (1) | AU2017374450B2 (enExample) |
| CL (1) | CL2019001617A1 (enExample) |
| DK (1) | DK3556349T3 (enExample) |
| ES (1) | ES2901427T3 (enExample) |
| IL (1) | IL267192B2 (enExample) |
| MX (1) | MX390841B (enExample) |
| MY (1) | MY200159A (enExample) |
| PL (1) | PL3556349T3 (enExample) |
| PT (1) | PT3556349T (enExample) |
| RU (1) | RU2761041C2 (enExample) |
| WO (1) | WO2018111000A1 (enExample) |
| ZA (1) | ZA201903748B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3711758T3 (fi) | 2017-11-14 | 2024-05-13 | Sk Biopharmaceuticals Co Ltd | Karbamaattiyhdisteen käyttö poissaolokohtauksen tai poissaolokohtausepilepsian ehkäisemiseksi, lievittämiseksi tai hoitamiseksi |
| MX2021003203A (es) * | 2018-09-21 | 2021-05-27 | Sk Biopharmaceuticals Co Ltd | Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico. |
| EP3854392A4 (en) * | 2018-09-21 | 2022-08-17 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US20100204178A1 (en) * | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| CN101309691A (zh) * | 2005-09-30 | 2008-11-19 | 奥瓦什医药品公司 | 新的胃肠外的卡马西平制剂 |
| CN101578103B (zh) * | 2006-06-29 | 2013-09-25 | 林科杰诺米克斯株式会社 | 抗生素的注射剂及其给予液 |
| US8343995B2 (en) * | 2007-04-27 | 2013-01-01 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
| BRPI0924997B1 (pt) | 2009-06-22 | 2024-01-16 | Sk Biopharmaceuticals Co., Ltd | Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
-
2017
- 2017-12-14 US US16/468,756 patent/US12070447B2/en active Active
- 2017-12-14 DK DK17880335.9T patent/DK3556349T3/da active
- 2017-12-14 KR KR1020197018404A patent/KR102605030B1/ko active Active
- 2017-12-14 MX MX2019006939A patent/MX390841B/es unknown
- 2017-12-14 ES ES17880335T patent/ES2901427T3/es active Active
- 2017-12-14 PL PL17880335T patent/PL3556349T3/pl unknown
- 2017-12-14 WO PCT/KR2017/014727 patent/WO2018111000A1/ko not_active Ceased
- 2017-12-14 JP JP2019531627A patent/JP7110196B2/ja active Active
- 2017-12-14 CN CN202410768574.7A patent/CN118766839A/zh active Pending
- 2017-12-14 AU AU2017374450A patent/AU2017374450B2/en active Active
- 2017-12-14 CN CN201780077651.2A patent/CN110267647A/zh active Pending
- 2017-12-14 RU RU2019121911A patent/RU2761041C2/ru active
- 2017-12-14 PT PT178803359T patent/PT3556349T/pt unknown
- 2017-12-14 MY MYPI2019003346A patent/MY200159A/en unknown
- 2017-12-14 EP EP17880335.9A patent/EP3556349B1/en active Active
-
2019
- 2019-06-10 IL IL267192A patent/IL267192B2/en unknown
- 2019-06-11 ZA ZA2019/03748A patent/ZA201903748B/en unknown
- 2019-06-12 CL CL2019001617A patent/CL2019001617A1/es unknown
-
2024
- 2024-07-22 US US18/779,456 patent/US20240374568A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118766839A (zh) | 2024-10-15 |
| RU2019121911A (ru) | 2021-01-15 |
| BR112019011914A2 (pt) | 2019-11-05 |
| JP2020502108A (ja) | 2020-01-23 |
| IL267192B2 (en) | 2023-05-01 |
| IL267192A (enExample) | 2019-07-31 |
| RU2019121911A3 (enExample) | 2021-03-05 |
| AU2017374450B2 (en) | 2023-05-11 |
| WO2018111000A1 (ko) | 2018-06-21 |
| US12070447B2 (en) | 2024-08-27 |
| MY200159A (en) | 2023-12-09 |
| JP7110196B2 (ja) | 2022-08-01 |
| KR102605030B1 (ko) | 2023-11-23 |
| MX390841B (es) | 2025-03-21 |
| CN110267647A (zh) | 2019-09-20 |
| PL3556349T3 (pl) | 2022-04-11 |
| IL267192B1 (en) | 2023-01-01 |
| PT3556349T (pt) | 2021-12-28 |
| US20240374568A1 (en) | 2024-11-14 |
| RU2761041C2 (ru) | 2021-12-02 |
| EP3556349A4 (en) | 2020-07-01 |
| ES2901427T3 (es) | 2022-03-22 |
| AU2017374450A1 (en) | 2019-07-04 |
| EP3556349A1 (en) | 2019-10-23 |
| DK3556349T3 (da) | 2022-01-03 |
| ZA201903748B (en) | 2020-12-23 |
| KR20190087568A (ko) | 2019-07-24 |
| US20190314336A1 (en) | 2019-10-17 |
| EP3556349B1 (en) | 2021-11-24 |
| CA3046458A1 (en) | 2018-06-21 |
| MX2019006939A (es) | 2019-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEAP202215378A (en) | Microbiocidal thiazole derivatives | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| CO2020007162A2 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| CR20150418A (es) | Compuestos de tetrahidropirrolotiazina | |
| MX2018003432A (es) | Compuestos heterociclicos y usos de los mismos. | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| AR112276A1 (es) | Polimorfos de 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona | |
| MX2019009185A (es) | Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende. | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| EA201891586A1 (ru) | Антипролиферативные соединения и их фармацевтические композиции и применения | |
| MY192425A (en) | Polymorphs | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| MX2020006016A (es) | Polimorfos. | |
| ECSP16096831A (es) | Derivados de naftiridinadiona | |
| SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة | |
| MX390841B (es) | Preparacion liquida parenteral que comprende compuesto de carbamato. | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2021009261A (es) | Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1. | |
| MX380217B (es) | Agonistas del receptor cxcr3. | |
| MX391363B (es) | Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor. |